• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Can A Surge In Activism Defeat American Big Pharma?

22/08/2018 by Guest contributor for Intellectual Property Watch Leave a Comment

By Vinayak Bhardwaj – Not a day passes in America without news of a drug company raising prices on prescription drugs. Americans pay two to six times more for prescription drugs than those living in other developed countries, who earn the same income.

Filed Under: IP Policies, Language, Themes, Venues, Contributors, English, Finance, Health & IP, Human Rights, Innovation/ R&D, Lobbying, North America, Patents/Designs/Trade Secrets, Regional Policy

Counter-Measures – How Startups Can Fight Pirates Without Burning Cash

03/08/2018 by Guest contributor for Intellectual Property Watch Leave a Comment

Patent litigation can drain capital during the crucial first few months of launching new technology, a particular problem in the capital-intensive hardware space. Companies need to find creative ways to go after patent thieves without stifling growth or ceding market share, writes Michael A. Nicolas.

Filed Under: Language, Themes, Venues, Contributors, Enforcement, English, Finance, North America, Regional Policy

Dangers Of Means Plus Function Limitations In US Patent Prosecution

19/07/2018 by Intellectual Property Watch 1 Comment

Broad patent protection is one of the goals when securing patent protection for inventions (i.e., new products and services). However, issues start to arise when the claim language becomes too broad. For example, broad claims might be construed as a means plus function limitation against the intentions of the patent prosecutor, and in some cases, those patents are invalidated as being indefinite. At least, this is the case with US patent prosecution. The patent laws of other jurisdictions treat means plus function style of claiming differently, and in my experience, less detrimental to the validity of the patent, writes James Yang.

Filed Under: Features, Inside Views, IP Policies, Themes, Venues, English, IP Law, North America, Patents/Designs/Trade Secrets, Regional Policy

Albania Introduces New Trademark Regulation

17/07/2018 by Guest contributor for Intellectual Property Watch 1 Comment

A new trademark regulation entered into force in Albania on June 7, 2018, clarifying a range of issues raised by the changes to the Albanian Industrial Property Law in force as of March 24, 2017. Some of the most significant changes and clarifications concern the following:

Filed Under: IP Policies, Language, Themes, Venues, Contributors, English, Europe, IP Law, Regional Policy, Trademarks/Geographical Indications/Domains

Excessive Pricing And Sham Patent Litigation: The Pfizer And AbbVie Decisions

03/07/2018 by Intellectual Property Watch 2 Comments

Frederick Abbott writes: Competition law is a critical tool in seeking to maintain some semblance of reasonable pricing in the pharmaceutical market. It is particularly important as legislators around the world appear extremely hesitant to address pharmaceutical pricing in meaningful ways, regrettably influenced by well-funded lobbying.

Two recent competition law decisions discussed below illustrate the importance of and challenges to regulating the pharmaceutical sector. In the first, the UK Competition Appeal Tribunal (CAT) partially upheld and partially reversed and remanded (pending briefing) a decision by the Competition and Markets Authority (CMA) fining Pfizer and Flynn close to £90 million for abuse of dominant position in the excessive pricing of an anti-epilepsy drug. The CAT decision is problematic because it creates unnecessary and unwarranted hurdles to findings of excessive pricing in the UK. In the second decision, the US Federal Trade Commission succeeds in proving that AbbVie engaged in abuse of monopoly power by engaging in sham patent litigation against two generic producers in order to delay market entry of competitive products. The Federal District Court found that AbbVie’s patent lawyers by “clear and convincing” evidence had knowingly pursued patent infringement claims without chance of success for no other purpose than to delay market entry.

Filed Under: Features, Inside Views, IP Policies, Language, Themes, Venues, English, Europe, Health & IP, IP Law, Innovation/ R&D, North America, Patents/Designs/Trade Secrets, Regional Policy

WTO Panel On Australia’s Tobacco Plain Packaging: A Fact Dependent Analysis Of TRIPS Art 20

03/07/2018 by Intellectual Property Watch 4 Comments

The WTO Panel’s long-awaited Reports in the four complaints against Australia’s tobacco plain packaging measures were circulated on 28 June 2018, more than 4 years since Panel establishment. Australia’s victory was absolute. It successfully defended its measures against every claim. Yet closer analysis of the Panel’s reasoning regarding specific provisions such as Article 20 of the TRIPS Agreement may cause some concern for policy-makers given how much the Panel’s conclusions relied on its assessment of the facts and evidence before it.

Filed Under: Features, Inside Views, IP Policies, Language, Themes, Venues, English, Health & IP, IP Law, Trademarks/Geographical Indications/Domains, WTO/TRIPS

Прекратить неавторизованный доступ к генетическим ресурсам (а именно, Биопиратство): принцип ограниченной открытости

19/06/2018 by Intellectual Property Watch Leave a Comment

«Доступ к генетическим ресурсам» и «справедливое и честное распределение выгод от их использования» были камнем предкновения на всех тринадцати Конференциях сторон-участников Соглашения Организации Объединенных Наций от 1993 года о Биологическом разнoобразии (CBD). Слова в кавычках составляют третью задачу договора, которая переплетена с двумя первыми, а именно с задачей консервации и устойчивого использования. По первым буквам английского названия эта задача сокращенно обозначается как «ABS». Несмотря на 25 лет усилий и при размерах био-экономики порядка 1 триллиона долларов [1], было заключено немного контрактов [2]. И в этом малом количестве контрактов денежная часть так незначительна, что их участники не пожелали ее обнародовать. «Закон ABS Бразилии» от 2015, который вошел в силу 6 ноября 2017, позволяет чтобы отчисления от суммы продаж составляли всего одну десятую процента[3]. Используя выражение известного ученого-законоведа, потребитель платит «пшик» авторам биоресурсов.

Filed Under: Features, Inside Views, IP Policies, Language, Themes, Venues, Biodiversity/Genetic Resources/Biotech, Enforcement, English, Environment, Human Rights, Patents/Designs/Trade Secrets, UPOV / CBD, United Nations - other Tagged With: #nofeed

Rethinking Article III Standing In IPR Appeals At The Federal Circuit (US)

18/06/2018 by Intellectual Property Watch 1 Comment

If the Federal Circuit will not correct its misplaced jurisprudence, then it is time for the Supreme Court to correct course, and bring into line the Federal Circuit’s IPR standing to appeal jurisprudence, with the Supreme Court’s (and other Circuits’) more forgiving law of allowing petitioners whose petitions are denied, to challenge such denials, particularly when Congress has set forth reasonable conditions, like Section 319, upon which such challenge is to occur, write Charles Macedo, Chandler Sturm, and James Howard.

Filed Under: Features, Inside Views, IP Policies, Language, Themes, Venues, English, IP Law, Innovation/ R&D, North America, Patents/Designs/Trade Secrets, Regional Policy

Deference, Not Delegation! – WIPO PCT Negotiations

17/06/2018 by Intellectual Property Watch 1 Comment

A new PCT Proposal seeks to amend the PCT Regulations so as to provide Member States to enter into a voluntary or opt-in arrangement that would allow such Member state to ‘outsource’ it’s patenting mechanism to another country/ regional treaty office even if it is not a member of such regional treaty. However, a patenting office with a full-fledged examination cadre acts a core component in capacity building for the Member State and serves to protect against imposition of TRIPs plus provisions by being an active part of the national policy discourse. Instead of opting in for full-fledged ‘outsourcing’ of their patenting function, it may be a better idea (in the long term) to develop their internal patent office cadre, develop appropriate IP policies best suited to their stage of development and at the same time, giving deference to the patenting decisions of like-minded countries. Developing countries will stand to benefit more by showing deference to decisions of like countries, rather than delegating the power to make those decisions. By granting a Contracting state the power to grant and reject patents of another State, this proposal could tantamount to introducing substantive patent law provisions through the backdoor: an endeavour to harmonize substantive patent law that the WIPO has failed to achieve over the years.

Filed Under: Features, Inside Views, IP Policies, Language, Themes, Venues, Access to Knowledge/ Education, Development, English, Innovation/ R&D, Patents/Designs/Trade Secrets, Technical Cooperation/ Technology Transfer, WIPO

En finir avec l’accès aux ressources génétiques sans autorisation (c’est-à-dire avec la biopiraterie): « l’ouverture limitée »

12/06/2018 by Intellectual Property Watch 1 Comment

L’ « accès aux ressources génétiques » et le « partage juste et équitable des avantages découlant de leur utilisation » s’est révelé un véritable casse-tête pour l’ensemble des 13 Conférences des Parties à la Convention des Nations Unies sur la Diversité Biologique (CDB). La formule, entre guillemets, qu’on désigne par l’acronyme « APA », se réfère au troisième objectif de la Convention, lequel est étroitement liée aux deux premiers, à savoir la conservation et l’utilisation durable de ces ressources. Malgré 25 années consécutives d’efforts et dans un contexte où le marché de la biotechnologie représente, annuellement, un trillion de dollars, peu d’accords APA ont été conclus jusqu’ici. Les bénéfices monétaires des quelques contrats existants sont si faibles que les contractants répugnent à les dévoiler. La « législation APA brésilienne » de 2015, qui est entrée en vigueur le 6 novembre 2017, permet par exemple d’offrir des royalties jusqu’à un dixième de pour cent du chiffre d’affaire. Selon les termes d’un éminent juriste: « les usagers paient des cacachuètes pour se servir de la biodiversité ».

Filed Under: Features, Inside Views, IP Policies, Language, Themes, Venues, Biodiversity/Genetic Resources/Biotech, Enforcement, Environment, Français, Human Rights, Patents/Designs/Trade Secrets, UPOV / CBD, United Nations - other

  • 1
  • 2
  • 3
  • …
  • 13
  • Next Page »
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2021 · Global Policy Reporting